HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma

Liu Li; Kuang Tianrui; Li Chunlei; Qiu Zhendong; Chen Xiaoyan; Deng Wenhong

doi:doi:10.18632/aging.204925

← Back

Research Paper Volume 15, Issue 16 pp 7997—8012

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma

Figure 5. Correlation between TMB, NAL, and HYDIN mutation status. Distribution of TMB (A) and NAL (B) in the total ICIs treatment cohort. (C) The Kaplan-Meier curves comparing OS among HYDIN^MUTTMB^high, HYDIN^MUTTMB^low/HYDIN^WTTMB^high, and HYDIN^WTTMB^low in the total ICIs treatment cohort. (D) The Kaplan-Meier curves comparing OS among HYDIN^MUTNAL^high, HYDIN^MUTNAL^low/HYDIN^WTNAL^high, and HYDIN^WTNAL^low in the total ICIs treatment cohort. HYDIN-MUT, HYDIN mutations; HYDIN-WT, HYDIN wild-type.